Use of plasma Epstein-Barr virus DNA monitoring as a tumor marker in follow-up of patients with nasopharyngeal carcinoma: Preliminary results and report of two cases

International Journal of Biological Markers

Volumn 22, Issue 3, 2007, Pages 194-199

  Ozyar E ^a   Gultekin M ^a   Alp, A ^a   Hascelik G ^a   Ugur, O ^a   Atahan, I L ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

EBV DNA; Nasopharyngeal carcinoma; Tumor marker

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; TAXANE DERIVATIVE; TUMOR MARKER; VIRUS DNA;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DNA DETERMINATION; ECHOGRAPHY; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NEEDLE BIOPSY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS;

HUMAN HERPESVIRUS 4;

EID: 36048960053     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.4019     Document Type: Article

References (14)

1. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997; 350; 1087-91.
2. Ozyar E, Ayhan A, Korcum AF, Atahan IL. Prognostic role of Ebstein-Barr virus latent membrane protein-1 and interleukin-10 expression in patients with nasopharyngeal carcinoma. Cancer Invest 2004; 22: 483-91.
3. Kiaris H, Ergazaki M, Segas J, Spandidos DA. Detection of Epstein-Barr virus genome in squamous cell carcinomas of the larynx. Int J Biol Markers 1995; 10: 211-5.
4. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res 1998; 4: 665-9.
5. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188-91.
6. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-70.
7. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995; 333: 693-8.
8. Ngan RK, Lau WH, Yip TT, et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann N Y Acad Sci 2001; 945: 73-9.
9. Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004; 22: 3053-60.
10. Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A. Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000; 6: 1046-51.
11. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-9.
12. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumornode-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24, 5414-8.
13. Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998; 16: 3550-5.
14. Makitie AA, Reis PP, Irish J, et al. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study. Head Neck 2004: 26: 815-22.